NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

About this update from Neuropace, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/76fa78216b26aa6985e0b90f0675b8aa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mDib4UeGbfviIfJrW0fQFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/76fa78216b26aa6985e0b90f0675b8aa","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/0LVF7e3ggmVcAv1QPU0IqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/76fa78216b26aa6985e0b90f0675b8aa","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/k2MK4OZ91bDPkeDgw8S1yQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/76fa78216b26aa6985e0b90f0675b8aa","width":1024,"height":512}},"lazy":false},{"type":"text","content":"--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--","length":163,"tagName":"p","attribs":{}},{"type":"text","content":"--NeuroPace to engage neurosurgeon community through clinical education, product feedback sessions, and hands-on booth demonstrations--","length":135,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 29, 2026--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive neuromodulation in epilepsy care, including long-term clinical outcomes with the RNS® System, NAUTILUS results in idiopathic generalized epilepsy (IGE), and the continued evolution of data-driven tools that support treatment planning, patient management and practice development.","length":726,"tagName":"p"},{"type":"text","content":""Neurosurgeons are essential to expanding access to device-based therapy for drug-resistant epilepsy," said Joel Becker, President and Chief Executive Officer of NeuroPace. "ASSFN gives us...

More updates from Neuropace, Inc.